J2350 HCPCS code: Injection, ocrelizumab, 1 mg
J2350 is the HCPCS Level II code for injection, ocrelizumab, 1 mg. In 2024 Medicare paid an average of $42.96 per service for J2350 across 4,887,519 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 600 per day on outpatient hospital claims. Medicare volume rose 2% from 2022 to 2024 (4,804,208 to 4,887,519 services). In 2024, about 1,903 clinicians billed Medicare for J2350 for 5,160 beneficiaries; Florida, Texas, New York accounted for 28% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2018-01-01 |
| Last action effective | 2018-01-01 |
Who bills J2350 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,903 |
| Medicare beneficiaries | 5,160 |
| States with claims | 42 |
| Share of services in top 3 states (Florida, Texas, New York) | 28% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J2350, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 4,804,208 | 5,154 | $53.98 | $43.12 |
| 2023 | 4,955,709 | 5,220 | $54.22 | $43.22 |
| 2024 | 4,887,519 | 5,160 | $53.90 | $42.96 |
States with the most J2350 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 570,186 | $44.18 |
| Texas | 403,837 | $39.75 |
| New York | 368,666 | $44.59 |
| California | 260,392 | $45.39 |
| Maryland | 240,349 | $44.90 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 600 | Prescribing Information |
| practitioner claims | 600 | Prescribing Information |
What changed for J2350
- 2018-01-01: J2350 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2350?
J2350 is the HCPCS Level II code for injection, ocrelizumab, 1 mg. Short descriptor: "Injection, ocrelizumab, 1 mg".
How much does Medicare pay for J2350?
In 2024, the average Medicare payment was $42.96 per service (average allowed $53.90).
Does Medicare cover J2350?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J2350 can be billed per day?
600 on outpatient hospital claims; 600 on practitioner claims (NCCI medically unlikely edits).
Related J23 codes
- J2300 — Injection, nalbuphine hydrochloride, per 10 mg
- J2305 — Injection, nitroglycerin, 5 mg
- J2310 — Injection, naloxone hydrochloride, per 1 mg
- J2311 — Injection, naloxone hydrochloride (zimhi), 1 mg
- J2312 — Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313 — Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315 — Injection, naltrexone, depot form, 1 mg
- J2320 — Injection, nandrolone decanoate, up to 50 mg
- J2323 — Injection, natalizumab, 1 mg
- J2325 — Injection, nesiritide, 0.1 mg
- J2326 — Injection, nusinersen, 0.1 mg
- J2327 — Injection, risankizumab-rzaa, intravenous, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2350
- Watch J2350 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2350
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.